<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4839">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01862302</url>
  </required_header>
  <id_info>
    <org_study_id>HALPCARD-2013</org_study_id>
    <nct_id>NCT01862302</nct_id>
  </id_info>
  <brief_title>Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium</brief_title>
  <acronym>HALPCARD</acronym>
  <official_title>Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium: A Randomized Placebo-Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Will the use of prophylactic Haloperidol for patients undergoing open heart surgery reduce
      the incidence, duration, and severity of post cardiotomy delirium?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot study for feasibility and safety, n = 40, haloperidol 1mg vs. placebo BID
      admisnistered night before and day of surgery, then continued for total 72hrs post-op, if
      delirium occurs study drug is stopped and ususal standard of care implemented by MRP.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Feasibility of conducting a trial utilizing low dose Haloperidol use in patients post cardiac surgery</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>If a participant does not develop delirium post operatively, then the confusion assessment method (CAM)will be monitored for 24 hours after the study medication ends. Patients will be followed up until seven days or until discharge if no delirium occurs, or if delirium is detected, up to 30 days or until discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety monitoring of low dose Haloperidol use in patients post cardiac surgery</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>If a participant does not develop delirium post operatively, then the confusion assessment method (CAM)will be monitored for 24 hours after the study medication ends. Patients will be followed up until seven days or until discharge if no delirium occurs, or if delirium is detected, up to 30 days or until discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of delirium</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium severity</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of stay (LOS), with breakdown for intensive care unit (ICU) days and ward days</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of delirium</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>An economic analysis will be completed to determine if Haloperidol prophylaxis resulted in any cost savings</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay to a maximum of 30 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Postoperative Confusion</condition>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol 1mg the night before and 1mg the morning of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 dose the night before and 1 dose the morning of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>1mg the night before and 1mg the morning of surgery</description>
    <arm_group_label>Haloperidol</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose the night before and 1 dose the morning of surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to 70 years of age, undergoing open heart surgery, with one of
             the following risk factors for post-op delirium:

               -  TIA/Stroke;

               -  Euroscore greater than or equal to 5;

               -  abnormal clock draw.

        Exclusion Criteria:

          -  Parkisonism,

          -  on any antipsychotic medications pre-op,

          -  active delirium,

          -  emergent surgery,

          -  Haloperidol allergy,

          -  schizophrenia,

          -  prolonged QTc.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Lamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andre Lamy, MD</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40325</phone_ext>
    <email>lamyand@hhsc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andre Lamy, MD</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>40325</phone_ext>
      <email>lamyand@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Lamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 25, 2013</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Andre Lamy</investigator_full_name>
    <investigator_title>Dr Andre Lamy, MD, FRCSC, MHSc, Cardiac Surgeon</investigator_title>
  </responsible_party>
  <keyword>Prevention delirium</keyword>
  <keyword>Cardiac surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Confusion</mesh_term>
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
